Every time Kim publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from Business ...

An experimental Maze Therapeutics drug increased urinary excretion of compounds that are biological indicators of metabolic disease, early clinical trial results that suggest the molecule has ...

Sanofi has two therapies for the rare disorder Pompe disease, one of which is a relatively recent entry into the market. But a drug candidate from Maze Therapeutics would offer advantages over both ...

Maze seeks as much as $133 mln in New York IPO Backers include Alphabet's GV and Third Rock Ventures Biotech IPOs set for ramp up in coming weeks Jan 27 (Reuters) - Drug developer Maze Therapeutics ...

Maze Therapeutics (NASDAQ:MAZE), which is developing treatments for chronic kidney disease, has filed to raise $100M through an initial public offering. While the company didn't disclose terms in its ...